These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 10722485

  • 1. Comparative pharmacodynamics of gatifloxacin and ciprofloxacin in an in vitro dynamic model: prediction of equiefficient doses and the breakpoints of the area under the curve/MIC ratio.
    Vostrov SN, Kononenko OV, Lubenko IY, Zinner SH, Firsov AA.
    Antimicrob Agents Chemother; 2000 Apr; 44(4):879-84. PubMed ID: 10722485
    [Abstract] [Full Text] [Related]

  • 2. Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses.
    Firsov AA, Lubenko IY, Vostrov SN, Kononenko OV, Zinner SH, Portnoy YA.
    J Antimicrob Chemother; 2000 Nov; 46(5):725-32. PubMed ID: 11062191
    [Abstract] [Full Text] [Related]

  • 3. A new approach to in vitro comparisons of antibiotics in dynamic models: equivalent area under the curve/MIC breakpoints and equiefficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibilities.
    Firsov AA, Vostrov SN, Shevchenko AA, Portnoy YA, Zinner SH.
    Antimicrob Agents Chemother; 1998 Nov; 42(11):2841-7. PubMed ID: 9797213
    [Abstract] [Full Text] [Related]

  • 4. Prediction of the effects of inoculum size on the antimicrobial action of trovafloxacin and ciprofloxacin against Staphylococcus aureus and Escherichia coli in an in vitro dynamic model.
    Firsov AA, Vostrov SN, Kononenko OV, Zinner SH, Portnoy YA.
    Antimicrob Agents Chemother; 1999 Mar; 43(3):498-502. PubMed ID: 10049257
    [Abstract] [Full Text] [Related]

  • 5. The pharmacodynamics of gatifloxacin and ciprofloxacin for pneumococci in an in vitro dynamic model: prediction of equiefficient doses.
    Zinner SH, Firsov AA, Gilbert D, Simmons K, Lubenko IY.
    J Antimicrob Chemother; 2001 Dec; 48(6):821-6. PubMed ID: 11733466
    [Abstract] [Full Text] [Related]

  • 6. Gemifloxacin and ciprofloxacin pharmacodynamics in an in-vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and doses.
    Firsov AA, Zinner SH, Lubenko IYu, Vostrov SN.
    Int J Antimicrob Agents; 2000 Dec; 16(4):407-14. PubMed ID: 11118849
    [Abstract] [Full Text] [Related]

  • 7. Prediction of the antimicrobial effects of trovafloxacin and ciprofloxacin on staphylococci using an in-vitro dynamic model.
    Firsov AA, Vasilov RG, Vostrov SN, Kononenko OV, Lubenko IY, Zinner SH.
    J Antimicrob Chemother; 1999 Apr; 43(4):483-90. PubMed ID: 10350376
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models.
    Andes D, Craig WA.
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1665-70. PubMed ID: 12019073
    [Abstract] [Full Text] [Related]

  • 10. Antistaphylococcal effect related to the area under the curve/MIC ratio in an in vitro dynamic model: predicted breakpoints versus clinically achievable values for seven fluoroquinolones.
    Firsov AA, Lubenko IY, Vostrov SN, Portnoy YA, Zinner SH.
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2642-7. PubMed ID: 15980331
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Bacterial strain-independent AUC/MIC and strain-specific dose-response relationships reflecting comparative fluoroquinolone anti-pseudomonal pharmacodynamics in an in vitro dynamic model.
    Lubenko IY, Vostrov SN, Portnoy YA, Zinner SH, Firsov AA.
    Int J Antimicrob Agents; 2002 Jul; 20(1):44-9. PubMed ID: 12127710
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Activity of gatifloxacin in an in vitro pharmacokinetic-pharmacodynamic model against Staphylococcus aureus strains either susceptible to ciprofloxacin or exhibiting various levels and mechanisms of ciprofloxacin resistance.
    Ba BB, Arpin C, Vidaillac C, Chausse A, Saux MC, Quentin C.
    Antimicrob Agents Chemother; 2006 Jun; 50(6):1931-6. PubMed ID: 16723548
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.